We are live on ! Find out more
THRD

Third Harmonic Bio

Delisted

THRD was delisted on the 30th of July, 2025.

99 hedge funds and large institutions have $134M invested in Third Harmonic Bio in 2025 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 36 increasing their positions, 13 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

262% more call options, than puts

Call options by funds: $286K | Put options by funds: $79K

177% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 13

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

10% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 29

3% more funds holding

Funds holding: 9699 (+3)

13.83% less ownership

Funds ownership: 99.76%85.93% (-14%)

71% less capital invested

Capital invested by funds: $463M → $134M (-$328M)

Holders
99
Holders Change
+3
Holders Change %
+3.13%
% of All Funds
1.33%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
32
Increased
36
Reduced
13
Closed
29
Calls
$286K
Puts
$79K
Net Calls
+$207K
Net Calls Change
+$206K
Name Holding Trade Value Shares
Change
Change in
Stake
AVLSA
1
Atlas Venture Life Science Advisors
Massachusetts
$36.1M
O
2
OrbiMed
New York
$20.1M
BCM
3
BML Capital Management
Indiana
$13.3M +$18.5M +3,824,417 New
NCM
4
Nantahala Capital Management
Connecticut
$10.2M +$11.8M +2,437,700 +487%
TCM
5
TCG Crossover Management
California
$8.69M
BI
6
BVF Inc
California
$8.23M
BlackRock
7
BlackRock
New York
$5.13M +$5.94K +1,225 +0.1%
Vanguard Group
8
Vanguard Group
Pennsylvania
$4.02M +$628K +129,613 +13%
TCM
9
Tang Capital Management
California
$3.23M +$3.78M +779,727 +520%
NM
10
Newtyn Management
New York
$2.2M +$3.08M +635,150 New
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$1.99M +$2.73M +562,334 +5,112%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.79M +$160K +33,028 +7%
State Street
13
State Street
Massachusetts
$1.51M +$61.5K +12,690 +3%
AAA
14
Affinity Asset Advisors
New York
$1.28M +$1.79M +370,000 New
Renaissance Technologies
15
Renaissance Technologies
New York
$1.15M +$990K +204,094 +160%
Morgan Stanley
16
Morgan Stanley
New York
$1.11M +$763K +157,343 +97%
RC
17
Rangeley Capital
Connecticut
$937K +$1.31M +270,000 New
JP Morgan Chase
18
JP Morgan Chase
New York
$918K +$1.11M +228,268 +631%
PLC
19
Peapod Lane Capital
New York
$777K +$1.09M +223,865 New
SCM
20
Stonepine Capital Management
Oregon
$738K +$1.03M +212,783 New
Northern Trust
21
Northern Trust
Illinois
$699K +$44.2K +9,113 +5%
6CM
22
683 Capital Management
New York
$694K +$970K +200,000 New
Charles Schwab
23
Charles Schwab
California
$615K +$19.2K +3,966 +2%
Qube Research & Technologies (QRT)
24
Qube Research & Technologies (QRT)
United Kingdom
$553K +$773K +159,374 New
Goldman Sachs
25
Goldman Sachs
New York
$548K +$249K +51,307 +48%

THRD Hedge Fund Activity: Q1 2025 in Review

99 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Third Harmonic Bio (THRD) for Q1 2025, worth a combined $134M — down 71% from $463M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new THRD positions and 29 closed out — a net gain of 3 holders — while 36 added to existing stakes and 13 trimmed.

The largest buyer was BML Capital Management, opening a new position worth an estimated $18.5M. The largest seller was General Atlantic, exiting entirely with an estimated $34.7M sold.

  • 99 institutional investors held Third Harmonic Bio (THRD) as of Q1 2025, up from 96 in Q4 2024.
  • Funds reported $134M of Third Harmonic Bio stock for Q1 2025, down 71% quarter-over-quarter.
  • 32 funds opened new Third Harmonic Bio positions in Q1 2025 and 29 closed out, a net change of +3 holders.
  • The largest Third Harmonic Bio buyer in Q1 2025 was BML Capital Management, an estimated $18.5M added.
  • The largest Third Harmonic Bio seller in Q1 2025 was General Atlantic, an estimated $34.7M sold.

Based on aggregated 13F filings for Q1 2025.